# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
JMP Securities analyst Silvan Tuerkcan reiterates CRISPR Therapeutics (NASDAQ:CRSP) with a Market Outperform and maintains $...
Wells Fargo analyst Yanan Zhu maintains CRISPR Therapeutics (NASDAQ:CRSP) with a Equal-Weight and lowers the price target fr...
Cantor Fitzgerald analyst Eric Schmidt reiterates CRISPR Therapeutics (NASDAQ:CRSP) with a Neutral.
Barclays analyst Gena Wang maintains CRISPR Therapeutics (NASDAQ:CRSP) with a Equal-Weight and lowers the price target from ...
Needham analyst Gil Blum maintains CRISPR Therapeutics (NASDAQ:CRSP) with a Buy and lowers the price target from $90 to $88.
Baird analyst Jack Allen maintains CRISPR Therapeutics (NASDAQ:CRSP) with a Neutral and raises the price target from $46 to...
CRISPR Therapeutics (NASDAQ:CRSP) reported quarterly losses of $(1.43) per share which missed the analyst consensus estimate of...
Citigroup analyst Yigal Nochomovitz maintains CRISPR Therapeutics (NASDAQ:CRSP) with a Buy and raises the price target from ...
Needham analyst Gil Blum reiterates CRISPR Therapeutics (NASDAQ:CRSP) with a Buy and maintains $90 price target.